Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
2011

Novel Therapies for Resistant Focal Segmental Glomerulosclerosis: Study Design

Sample size: 126 publication Evidence: moderate

Author Information

Author(s): Trachtman Howard, Vento Suzanne, Gipson Debbie, Wickman Larysa, Gassman Jennifer, Joy Melanie, Savin Virginia, Somers Michael, Pinsk Maury, Greene Tom

Primary Institution: Cohen Children's Medical Center of New York

Hypothesis

Can novel antifibrotic therapies improve outcomes in patients with resistant focal segmental glomerulosclerosis?

Conclusion

The FONT II trial aims to identify effective treatments for resistant focal segmental glomerulosclerosis through a flexible Phase II study design.

Supporting Evidence

  • FSGS is a serious kidney disease that often does not respond to standard treatments.
  • Adalimumab and galactose are being tested as new treatment options.
  • The study aims to find effective therapies to prevent kidney failure.

Takeaway

This study is trying to find new medicines that can help kids and adults with a serious kidney problem called FSGS when regular treatments don't work.

Methodology

A multicenter Phase I/II randomized controlled trial comparing adalimumab and galactose against standard conservative therapy.

Potential Biases

Potential bias in patient selection and response assessment due to the open-label design.

Limitations

The study may not generalize to all patients with FSGS due to specific inclusion and exclusion criteria.

Participant Demographics

Patients aged 1-51 years with primary FSGS confirmed by renal biopsy.

Digital Object Identifier (DOI)

10.1186/1471-2369-12-8

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication